Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1829-1838

  Waldron, Nate N ^a   Kaufman, Dan S ^b   Oh, Seunguk ^c   Inde, Zintis ^c   Hexum, Melinda K ^b   Ohlfest, John R ^b   Vallera, Daniel A ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; GLYCOSYLATED PROTEIN; HYBRID PROTEIN; PROTEIN DCD133KDEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CD34 SELECTION; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DEGRADATION; FEMALE; GENE FUSION; GROWTH INHIBITION; HEAD AND NECK CANCER; HEMATOPOIETIC CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STEM CELL; XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIGENS, CD; BACTERIAL TOXINS; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; EXOTOXINS; FEMALE; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PEPTIDES; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054003177     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0206     Document Type: Article

References (44)

1. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 2009;1:12-25.
2. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-82. (Pubitemid 39382161)
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11. (Pubitemid 33041634)
4. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-2.
5. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Onc 2008;26:2839-45.
6. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008;26:2795-9.
7. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12. (Pubitemid 28007217)
8. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8. (Pubitemid 30062717)
9. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000;97:14720-5. (Pubitemid 32016642)
10. Fabrizi E, di Martino S, Pelacchi F, Ricci-Vitiani L. Therapeutic implications of colon cancer stem cells. World J Gastroenterol 2010;16:3871-7.
11. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007;36:594-603. (Pubitemid 47609813)
12. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
13. Du Z, Qin R, Wei C, Wang M, Shi C, Tian R, et al. Pancreatic cancer cell resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci 2011;56:741-50.
14. Fitzgerald D, Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 1989;81:1455-63. (Pubitemid 19252396)
15. Pavon LF, Gamarra LF, Marti LC, Amaro Junior E, Moreira-Filho CA, Camargo-Mathias MI, et al. Ultrastructural characterization of CD133+ stem cells bound to superparamagnetic nanoparticles: possible biotechnological applications. J Microsc 2008;231:374-83.
16. Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ, Maccallum J. In vivo investigation of CD133 as a putative marker of cancer stem cells in HEP-2 cell line. Head Neck 2009;31:94-101.
17. Friedman S, Min L, Schultz A, Thomas D, Lin RY. CD133+ Anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 2009;4:e5395.
18. Swaminathan SK, Olin MR, Forster CL, Cruz KS, Panyam J, Ohlfest JR. Identification of a novel monoclonal antivody recognizing CD133. J Immunol Methods 2010;361:110-5.
19. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983-90.
20. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1,000 molecules per cell are sufficient for complete responses. Cancer Res 1998;58:968-75. (Pubitemid 28182466)
21. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 1995;307:29-37.
22. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B-cell epitopes. Proc Natl Acad Sci U S A 2008;105:11311-6.
23. Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA. Design and modification of EGF4KDEL 7mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 2009;101:1114-23.
24. Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol 2011;103:255-66.
25. Vallera DA, Oh S, Chen H, Shu Y, Frankel AE. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther 2010;9:1872-83.
26. Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP. Genetic alteration of a bispecific ligand directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic. Leuk Res 2009;33:1233-42.
27. Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP, et al. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132:668-77. (Pubitemid 43927046)
28. Abu-Ali S, Fotovati A, Shirasuna K. Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers. Mol Cancer 2008;7:47.
29. Tian X, Kaufman DS. Hematopoietic development of human embryonic stem cells in culture. Methods Mol Biol 2008;430:119-33.
30. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23:1-13.
31. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7. (Pubitemid 27298715)
32. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010;70:719-29.
33. Zhu W, Hai T, Ye L, Cote GJ. Medullary thyroid carcinoma cell lines contain a self-renewing CD133 +population that is dependent on ret proto-oncogene activity. J Clin Endocrinol Metab 2010;95:439-44.
34. Beier F, Beier CP, Aschenbrenner I, Hildebrandt GC, Brümmendorf TH, Beier D. Identification of CD133-/telomerase low progenitor in glioblastoma-derived cancer stem cell lines. Cell Mol Neurobiol 2011;31:337-43
35. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glio-blastoma. Cancer Cell 2010;17:362-75.
36. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
37. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-7.
38. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Antimesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007;13:7166-71. (Pubitemid 350276903)
39. Pearson JW, Sivam G, Manger R, Wiltrout RH, Morgan AC Jr, Longo DL. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res 1989;49:4990-5. (Pubitemid 19239331)
40. Rutella S, Bonanno G, Marone M, De Ritis D, Mariotti A, Voso MT, et al. Identification of a novel subpopulation of human cord blood CD34- CD133- CD7- CD45+ lineage-cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J Immunol 2003;171:2977-88. (Pubitemid 37093520)
41. Suuronen EJ, Wong S, Kapila V, Waghray G, Whitman SC, Mesana TG, et al. Generation of CD133+ cells from CD133- peripheral blood mononuclear cells and their properties. Cardiovasc Res 2006;70:126-35.
42. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-9. (Pubitemid 351920235)
43. Sehl ME, Sinsheimer JS, Zhou H, Lange KL. Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res 2009;69:9481-9.
44. Sgambato A, Puglisi MA, Errico F, Rafanelli F, Boninsegna A, Rettino A, et al. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. J Cell Physiol 2010;224:234-41.